Payment overview · 2025
General Payments
$2,855.55
126 reported records · 30 companies
Healthcare provider profile · identity verified
Naiff Ali, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DEARBORN HEIGHTS, MI · NPI 1992151401
Verified facts
What the public records show
CMS Open Payments records show Naiff Ali, M.D. received $2,855.55 in general payments during 2025 across 126 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $919.74 | 32.2% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $335.74 | 11.8% | 17 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $255.86 | 9.0% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $237.20 | 8.3% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $178.33 | 6.2% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $139.64 | 4.9% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $80.81 | 2.8% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $71.07 | 2.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.27 | 2.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $63.88 | 2.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.45 | 2.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.37 | 1.4% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.89 | 1.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.45 | 1.3% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $30.21 | 1.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $29.77 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.74 | 1.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.01 | 1.0% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.95 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.65 | 0.8% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $21.26 | 0.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.57 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.45 | 0.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.79 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.51 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.49 | 0.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.99 | 0.5% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $14.44 | 0.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.91 | 0.5% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $9.11 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,855.55 | 126 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $545.63 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $317.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $275.47 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $255.86 | 16 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.83 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $121.33 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.37 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $115.37 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.50 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $78.99 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $71.07 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $70.89 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $68.75 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $66.50 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.27 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.37 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $39.89 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $36.45 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.57 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.85 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.85 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $30.21 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.74 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.74 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.01 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.01 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| Linzess Normalized: linzess |
Drug | IRONWOOD PHARMACEUTICALS, INC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $11.84 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $9.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 13 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 289 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
| Linzess linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 106 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 210 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 49 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
289 | 99 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
210 | 66 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
106 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
106 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
73 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
289 | 99 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1171 | 374 |
| Amlodipine Besylate | Amlodipine Besylate | 617 | 212 |
| Omeprazole | Omeprazole | 548 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 527 | 193 |
| Lisinopril | Lisinopril | 520 | 197 |
| Metformin Hcl | Metformin Hcl | 494 | 181 |
| Losartan Potassium | Losartan Potassium | 445 | 169 |
| Tamsulosin Hcl | Tamsulosin Hcl | 437 | 136 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 401 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 380 | 122 |
| Carvedilol | Carvedilol | 349 | 119 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 343 | 125 |
| Gabapentin | Gabapentin | 328 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 298 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 112 |
| Eliquis | Apixaban | 289 | 99 |
| Clopidogrel | Clopidogrel Bisulfate | 253 | 92 |
| Furosemide | Furosemide | 245 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 240 | 92 |
| Alprazolam | Alprazolam | 237 | 105 |
| Famotidine | Famotidine | 233 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 221 | 114 |
| Simvastatin | Simvastatin | 210 | 73 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 210 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 68 |
| Prednisone | Prednisone | 183 | 121 |
| Potassium Chloride | Potassium Chloride | 181 | 66 |
| Montelukast Sodium | Montelukast Sodium | 169 | 61 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 165 | 75 |
| Hydralazine Hcl | Hydralazine Hcl | 147 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 147 | 51 |
| Allopurinol | Allopurinol | 140 | 56 |
| Ibuprofen | Ibuprofen | 140 | 54 |
| Jardiance | Empagliflozin | 138 | 49 |
| Bumetanide | Bumetanide | 137 | 60 |
| Sertraline Hcl | Sertraline Hcl | 133 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 44 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 128 | 104 |
| Meloxicam | Meloxicam | 128 | 39 |
| Trazodone Hcl | Trazodone Hcl | 125 | 39 |
| Donepezil Hcl | Donepezil Hcl | 119 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 113 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 27 |
| Finasteride | Finasteride | 111 | 32 |
| Spironolactone | Spironolactone | 111 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 109 | 38 |
| Tramadol Hcl | Tramadol Hcl | 107 | 48 |
| Mounjaro | Tirzepatide | 106 | 29 |
| Xarelto | Rivaroxaban | 106 | 37 |
| Azithromycin | Azithromycin | 99 | 78 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 39 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 92 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 27 |
| Atenolol | Atenolol | 90 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 87 | 35 |
| Ezetimibe | Ezetimibe | 85 | 29 |
| Meclizine Hcl | Meclizine Hcl | 83 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 28 |
| Buspirone Hcl | Buspirone Hcl | 78 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 24 |
| Methylprednisolone | Methylprednisolone | 76 | 69 |
| Nifedipine Er | Nifedipine | 76 | 28 |
| Januvia | Sitagliptin Phosphate | 74 | 23 |
| Entresto | Sacubitril/Valsartan | 73 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 22 |
| Pregabalin | Pregabalin | 70 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 26 |
| Farxiga | Dapagliflozin Propanediol | 63 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 14 |
| Sucralfate | Sucralfate | 60 | 17 |
| Bupropion Xl | Bupropion Hcl | 59 | 17 |
| Glipizide | Glipizide | 58 | 23 |
| Methocarbamol | Methocarbamol | 58 | 27 |
| Clonidine Hcl | Clonidine Hcl | 57 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 25 |
| Alendronate Sodium | Alendronate Sodium | 54 | 17 |
| Cephalexin | Cephalexin | 54 | 34 |
| Digoxin | Digoxin | 54 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 45 |
| Ozempic | Semaglutide | 51 | 16 |
| Diazepam | Diazepam | 48 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 43 |
| Glimepiride | Glimepiride | 48 | 16 |
| Ketoconazole | Ketoconazole | 47 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 27 |
| Chlorthalidone | Chlorthalidone | 44 | 13 |
| Fluconazole | Fluconazole | 43 | 20 |
| Torsemide | Torsemide | 43 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 17 |
| Hydrocortisone | Hydrocortisone | 42 | 17 |
| Memantine Hcl | Memantine Hcl | 40 | 16 |
| Mirtazapine | Mirtazapine | 40 | 11 |
| Warfarin Sodium | Warfarin Sodium | 40 | 12 |
| Calcitriol | Calcitriol | 39 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 38 | 16 |
| Glipizide Er | Glipizide | 38 | 14 |
| Myrbetriq | Mirabegron | 38 | 14 |
| Metformin Hcl Er | Metformin Hcl | 36 | 15 |
| Naproxen | Naproxen | 34 | 14 |
| Nitroglycerin | Nitroglycerin | 33 | 20 |
| Ammonium Lactate | Ammonium Lactate | 32 | 14 |
| Celecoxib | Celecoxib | 32 | 12 |
| Fenofibrate | Fenofibrate | 32 | 12 |
| Lidocaine | Lidocaine | 32 | 11 |
| Mupirocin | Mupirocin | 32 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | 11 |
| Levetiracetam | Levetiracetam | 31 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 23 |
| Colesevelam Hcl | Colesevelam Hcl | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Nystatin | Nystatin | 29 | 19 |
| Ramipril | Ramipril | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 15 |
| Lorazepam | Lorazepam | 28 | 16 |
| Ondansetron Odt | Ondansetron | 28 | 22 |
| Topiramate | Topiramate | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 24 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Colchicine | Colchicine | 25 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 25 | 15 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 16 |
| Baclofen | Baclofen | 21 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | 14 |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | 11 |
| Latanoprost | Latanoprost | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Hydroxyurea | Hydroxyurea | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,855.55 · 126 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, APTIMA, AREXVY, ARISTADA, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fibroscan, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Korlym, LEQVIO, LYBALVI, Linzess, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, Symbravo, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, TZIELD, UBRELVY, VERQUVO, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error